Trastuzumab achieves slight reduction in recurrence for women with HER2-positive DCIS

May 29, 2020

The addition of the monoclonal antibody therapy Trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) on the NRG Oncology clinical trial NSABP B-43. The trial did find a statistically non-significant, modest (19%) reduction in the rate of recurrence among women that received trastuzumab, but this difference was not statistically significant. These results were recently exhibited during an oral presentation at the virtual Annual Meeting of the American Society for Clinical Oncology.

The Phase III NRG-NSABP B-43 trial accrued 2014 women and randomly assigned trial participants in a 1:1 fashion to receive either whole-breast radiotherapy alone or radiotherapy with two doses of trastuzumab following lumpectomy. The goal of the trial was to determine if the addition of trastuzumab can assist in preventing recurrence of ipsilateral breast cancer, ipsilateral skin cancer, ipsilateral DCIS, or ipsilateral breast tumor recurrence in women with DCIS. This hypothesis was developed in response to data from previous preclinical studies that suggested that trastuzumab can boost the effectiveness of radiotherapy.

Of the 2014 patients that were accrued to the trial, 1998 patients (99.2%) had follow up information available at the median follow up time point of 79.2 months. 2001 women had radiotherapy information; 98.2% of patients completed radiotherapy treatment on the radiotherapy alone treatment arm (RT) and 98.1% completed radiotherapy on the radiotherapy plus trastuzumab arm (RT+T). In the RT+T group, 94.3% patients completed both doses of trastuzumab therapy, while 2.5% had only one dose of the therapy. Another 3.2% did not start trastuzumab.

The NRG-NSABP B-43 protocol required that 163 in-breast tumor recurrence (IBTR) events be confirmed or that all patients be on study for at least five years to trigger a definitive analysis. Since less than 163 IBTR events were confirmed, analysis was performed because all patients were on the trial for five years or longer.

At this preliminary analysis based on information through December 31, 2019, 114 IBTR events were confirmed with 63 being in the RT arm and 51 in the RT+T treatment arm. In those that had a recurrence, 38 were invasive including 18 in the RT arm and 20 in the RT+T treatment arm. The remaining 76 IBTR events were DCIS with 45 in the RT treatment arm and 31 in the RT+T treatment arm. Annual IBTR event rates were 0.99% per year in the RT group and 0.80% per year in the RT+T group. There were 48 deaths on the trial with 26 in the RT arm and 22 in the RT+T arm.

"This is the first prospective, randomized study of HER2-targeted treatment for HER2-positive DCIS. It provides important insight into the natural history and impact of HER2-targeted treatment on outcomes," stated Melody Cobleigh, MD, of Rush University Medical Center and the lead author of the NRG-NSABP B-43 abstract.
This study was supported by the National Cancer Institute grants U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology SDMC), UG1CA189867 (NRG Oncology NCORP) as well as support from Genentech. NSABP B-43 was sponsored by National Cancer Institute (NCI), part of the National Institutes of Health. Genentech provided trastuzumab to support the study through a Collaborative Research and Development Agreement with NCI.


Cobleigh, M; Anderson, S; Siziopikou, K; Arthur, D; Julian, T; Rabinovitch, R; Parda, D; Seaward, S; Carter, D; Lyons, J; Dillmon, M; Magrinat, G; Kavadi, V; Zibelli, A; Tiriveedhi, L; Hill, M; Melnick, M; Beriwal, S; Mamounas, E; Wolmark, N. Primary results of NRG Oncology / NSABP B-43: Phase III trial comparing concurrent trastuzumab (T) and radiation therapy (RT) with RT alone for women with HER2-positive ductal carcinoma in situ (DCIS) after lumpectomy. Abstract presented at the virtual Annual Meeting of the American Society of Clinical Oncology (ASCO).

About NRG Oncology

NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of patients with cancer. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that integrates the research of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). The research network seeks to carry out clinical trials with emphases on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology's extensive research organization comprises multidisciplinary investigators, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians, and encompasses more than 1,300 research sites located world-wide with predominance in the United States and Canada. NRG Oncology is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI's National Clinical Trials Network.

NRG Oncology

Related Radiotherapy Articles from Brightsurf:

Genomic analysis predicts survival benefit of adjuvant chemotherapy following radiotherapy over radiotherapy alone in low-grade gliomas in NRG Oncology clinical trial
A practice-changing study, NRG Oncology clinical trial NRG-RTOG 9802, has demonstrated, for the first time, a survival benefit of adjuvant chemotherapy following radiotherapy over radiotherapy alone in certain subgroups of patients with high-risk, low-grade glioma (WHO classification: LGG, grade II), a type of brain tumor that originates from glial cells.

Outcomes in radiotherapy-treated patients with cancer during COVID-19
The delivery of radiotherapy in 209 patients with cancer during the COVID-19 outbreak in Wuhan, China, is evaluated in this case series.

Shorter radiotherapy treatment for bowel cancer patients during COVID-19
An international panel of cancer experts has recommended a one-week course of radiotherapy and delaying surgery as the best way to treat patients with bowel cancer during the COVID-19 pandemic.

The pros and cons of radiotherapy: Will it work for you?
Women undergoing radiotherapy for many cancers are more likely than men to be cured, but the side effects are more brutal, according to one of Australia's most experienced radiation oncology medical physicists.

How to keep boron inside cells during radiotherapy: a novel approach to cancer treatment
Boron neutron capture therapy (BNCT) is a technique in which p-boronophenylalanine (BPA) is transferred to cancer cells, and the boron in it undergoes nuclear fission reaction upon irradiation of thermal neutrons, releasing high energy particles that kill the cells.

Prolonged breath-holding could help radiotherapy treatment of cardiac arrhythmias
A technique that enables patients suffering from heart conditions to hold their breath safely for over five minutes could have potential as part of a new treatment for cardiac arrhythmias, say researchers at the University of Birmingham.

Zebrafish 'avatars' can help decide who should receive radiotherapy treatment
To date, there is no method for clearly determining whether radiotherapy will be an effective treatment for individual cancer patients.

One dose of radiotherapy as effective as five doses for cancer in the spine
A single dose of radiotherapy is as 'effective' as five doses for end-of-life cancer patients suffering with painful spinal canal compression, finds a large study conducted by UCL.

Personalized and powerful: UK to lead next-generation radiotherapy research
The UK will be transformed into a global hub for radiotherapy research, pioneering the use of the latest techniques such as FLASH radiotherapy and artificial intelligence, with a new £56 million research network announced by Cancer Research UK today.

Oxygen in hyperbaric chamber provides relief after radiotherapy
Hyperbaric oxygen therapy (HBOT) can relieve self-reported symptoms and side-effects of radiotherapy against cancer in the pelvic region, a study shows.

Read More: Radiotherapy News and Radiotherapy Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to